Innovent Biologics’ shares surged nearly 13% to a record high on Wednesday, outpacing the broader market after the company reported robust first-half financial results.
The Hong Kong-listed biotech reached HK$112.7 per share, marking its peak valuation, while the Hang Seng index gained 0.8% for the session. Innovent’s H1 2026 revenue rose 45% year-over-year to RMB 8.6 billion, driven by a 57% increase in product revenue to RMB 8.2 billion. IFRS net profit climbed 50% to RMB 1.3 billion, supported by strong commercial performance in oncology and chronic disease treatments.
The company’s cash position strengthened to RMB 30.2 billion, providing a substantial financial cushion. Innovent also outlined a 2030 strategic vision aimed at achieving RMB 35-40 billion in revenue, signaling a pivot from a China-centric model toward a global biopharma platform.
The stock’s performance positioned it as the top performer on the Hang Seng index for the day, reflecting investor confidence in its growth trajectory and operational execution.
